Source comparison
Comparison: Thymosin Alpha-1 Product Quality Factors
Synthesis Method Solid-phase peptide synthesis with stepwise amino acid coupling Bacterial or yeast expression with affinity purification Unspecified or unreported method SPPS provides exact sequence control; recombinant risks endotoxin contamination Typical P
This comparison does not assign a generated winner or score.
- Synthesis Method
- Solid-phase peptide synthesis with stepwise amino acid coupling
- Bacterial or yeast expression with affinity purification
- Unspecified or unreported method
- SPPS provides exact sequence control; recombinant risks endotoxin contamination
- Typical Purity
- 98.0–99.5% HPLC-verified
- 95.0–98.0% HPLC-verified
- 90.0–96.0% claimed (often unverified)
- ≥98% HPLC purity is minimum for immune research applications
- Endotoxin Level
- <0.1 EU/mg
- 0.5–5.0 EU/mg
- Often not tested or reported
- Endotoxin >0.1 EU/mg activates monocytes and confounds T-cell assays
- N-Terminal Acetylation
- Always present (required for activity)
- Variable (sometimes incomplete)
- Often absent or not verified
- Non-acetylated peptide loses 80% activity within 30 minutes
- Cost per 10mg Vial
- $180–$320
- $80–$150
- $40–$100
- Price reflects synthesis rigor and quality control investment
- Ideal Use Case
- Immune modulation research, T-cell assays, dendritic cell studies
- Non-immune applications where endotoxin tolerance exists
- Not recommended for research requiring precise immune baseline control
- Choose synthesis method based on protocol's endotoxin sensitivity